105 related articles for article (PubMed ID: 11512406)
1. [Positron emission tomography (PET): application in urogenital system oncologic diseases].
Lomeña F; Simó M; Setoain X; Pérez G
Arch Esp Urol; 2001; 54(6):649-60. PubMed ID: 11512406
[TBL] [Abstract][Full Text] [Related]
2. [Positron emission tomography. Introduction of a new procedure in diagnosis of urologic tumors and initial clinical results].
Bachor R; Kocher F; Gropengiesser F; Reske SN; Hautmann RE
Urologe A; 1995 Mar; 34(2):138-42. PubMed ID: 7754585
[TBL] [Abstract][Full Text] [Related]
3. [Positron emission tomography (PET) for diagnosis and monitoring of treatment for urological tumors].
Machtens S; Boerner AR; Hofmann M; Knapp WH; Jonas U
Urologe A; 2004 Nov; 43(11):1397-409. PubMed ID: 15502907
[TBL] [Abstract][Full Text] [Related]
4. Nuclear medicine studies of the prostate, testes, and bladder.
Jana S; Blaufox MD
Semin Nucl Med; 2006 Jan; 36(1):51-72. PubMed ID: 16356796
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and monitoring of urological tumors using positron emission tomography.
Hofer C; Kübler H; Hartung R; Breul J; Avril N
Eur Urol; 2001 Nov; 40(5):481-7. PubMed ID: 11752853
[TBL] [Abstract][Full Text] [Related]
6. Molecular positron emission tomography and PET/CT imaging in urological malignancies.
Powles T; Murray I; Brock C; Oliver T; Avril N
Eur Urol; 2007 Jun; 51(6):1511-20; discussion 1520-1. PubMed ID: 17275167
[TBL] [Abstract][Full Text] [Related]
7. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000.
Reske SN; Kotzerke J
Eur J Nucl Med; 2001 Nov; 28(11):1707-23. PubMed ID: 11702115
[TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography in urologic oncology.
Shvarts O; Han KR; Seltzer M; Pantuck AJ; Belldegrun AS
Cancer Control; 2002; 9(4):335-42. PubMed ID: 12228759
[TBL] [Abstract][Full Text] [Related]
9. PET in the management of urologic malignancies.
Kumar R; Zhuang H; Alavi A
Radiol Clin North Am; 2004 Nov; 42(6):1141-53, ix. PubMed ID: 15488563
[TBL] [Abstract][Full Text] [Related]
10. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.
Wiering B; Krabbe PF; Jager GJ; Oyen WJ; Ruers TJ
Cancer; 2005 Dec; 104(12):2658-70. PubMed ID: 16315241
[TBL] [Abstract][Full Text] [Related]
11. [Positron-emission tomography with fluorine-18-deoxyglucose in the staging and control of patients with lymphoma. Comparison with clinico-radiologic assessment].
Mainolfi C; Maurea S; Varrella P; Alaia C; Imparato C; Alfano B; Abate G; Bazzicalupo L
Radiol Med; 1998; 95(1-2):98-104. PubMed ID: 9636735
[TBL] [Abstract][Full Text] [Related]
12. Positron emission tomography imaging in evaluation of cancer patients.
Kumar R; Bhargava P; Bozkurt MF; Zhuang H; Potenta S; Alavi A
Indian J Cancer; 2003; 40(3):87-100. PubMed ID: 14716112
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography for urological tumours.
Hain SF; Maisey MN
BJU Int; 2003 Jul; 92(2):159-64. PubMed ID: 12823366
[TBL] [Abstract][Full Text] [Related]
14. [Contribution of positron emission tomography for the management of lung cancer].
Bury T; Rigo P
Rev Pneumol Clin; 2000 Apr; 56(2):125-31. PubMed ID: 10810198
[TBL] [Abstract][Full Text] [Related]
15. Clinical role of FDG PET in evaluation of cancer patients.
Kostakoglu L; Agress H; Goldsmith SJ
Radiographics; 2003; 23(2):315-40; quiz 533. PubMed ID: 12640150
[TBL] [Abstract][Full Text] [Related]
16. Economic analyses on the use of positron emission tomography for the work-up of solitary pulmonary nodules and for staging patients with non-small-cell-lung-cancer in Italy.
Gugiatti A; Grimaldi A; Rossetti C; Lucignani G; De Marchis D; Borgonovi E; Fazio F
Q J Nucl Med Mol Imaging; 2004 Mar; 48(1):49-61. PubMed ID: 15195004
[TBL] [Abstract][Full Text] [Related]
17. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma.
Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Bares R; Claussen CD; Kanz L; Bokemeyer C
Cancer; 2002 May; 94(9):2353-62. PubMed ID: 12015760
[TBL] [Abstract][Full Text] [Related]
18. Role of FDG-PET in the assessment of survival prognosis in melanoma.
Pleiss C; Risse JH; Biersack HJ; Bender H
Cancer Biother Radiopharm; 2007 Dec; 22(6):740-7. PubMed ID: 18158764
[TBL] [Abstract][Full Text] [Related]
19. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG
J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536
[TBL] [Abstract][Full Text] [Related]
20. PET in genitourinary tract cancers.
Fanti S; Nanni C; Ambrosini V; Gross MD; Rubello D; Farsad M
Q J Nucl Med Mol Imaging; 2007 Sep; 51(3):260-71. PubMed ID: 17464269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]